Please login to the form below

Acadia

This page shows the latest Acadia news and features for those working in and with pharma, biotech and healthcare.

Acadia’s Nuplazid misses the mark in major depressive disorder trial

In 2016, Acadia won US Food and Drug Administration (FDA) approval for Nuplazid as a treatment for Parkinson’s disease-associated psychosis, the first therapy approved in this setting. ... The schizophrenia trial, like the MDD trial, was viewed as one

Latest news

Intra-Cellular soars on FDA approval of schizophrenia drug

This includes Sage Therapeutics, Acadia Pharmaceutical, Karuna Therapeutics and even Biogen, which is looking for approval of its controversial Alzheimer’s drug.
Acadia’s drive to extend use of Nuplazid hits a wall

The drug has failed the late-stage ENHANCE trial in schizophrenia inadequately controlled by currently-approved drugs, viewed as one of Acadia’s biggest opportunities to extend the franchise. ... Shares in Acadia were down 16% remarket in the wake of
New leader at Medivir after setbacks

s board in May having previously had a 15-year stint as CEO of Acadia Pharma which came to end in 2015 after the company was forced to delay a filing
Nuplazid backed by FDA panel as first-ever Parkinson's psychosis drug

Concludes Acadia Pharmaceuticals’ drug provides ‘modest but meaningful’ benefits. Acadia Pharmaceuticals is celebrating an FDA panel verdict that could set its Nuplazid drug up to be the first approved therapy for ... However, there were some
Clouded vision

AGN 203818 is an orally active, α-adrenoreceptor agonist that was discovered as part of a research programme between Allergan and ACADIA.

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Jacob Plieth at Vantage recently highlighted this trend, with companies like Tesaro, Clovis Oncology and Acadia failing to meet revenue expectations for their new launches.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Damien McDevitt moves from GSK to Acadia Pharmaceuticals

US biopharmaceutical company Acadia Pharmaceuticals has appointed Damien McDevitt (pictured) as senior vice president of corporate development. ... Meanwhile, Acadia’s SVP, technology development and operations Jim Nash will retire in January.
Juniper Pharmaceuticals adds to board of directors

Dr Gray has over 20 years of biotechnology and biopharmaceutical experience and is the owner and president of Gray Strategic Advisors as well as serving on the boards of Acadia Pharmaceuticals,
Srdjan Stankovic joins Acadia Pharmaceuticals

He moves to the San Diego biopharma from Alkermes. San Diego biopharmaceutical company Acadia Pharmaceuticals has appointed Srdjan (Serge) Stankovic as executive vice president, head of research and development. ... Steve Davis, Acadia's president

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months: A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up: COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020: In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...